Evidence map›Paper›PMID 16364461›Full record

ArticleBehavioural brain research2006

Selective increase of dark phase water intake in neuropeptide-Y Y2 and Y4 receptor knockout mice.

Thomas Wultsch, Evelin Painsipp, Sabine Donner, Günther Sperk, Herbert Herzog, Bernhard A Peskar, Peter Holzer

Abstract readComparative Study
In one paragraph

Article in Behavioural brain research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neuropeptide Y Y2 receptor in health and disease.British journal of pharmacology · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Thomas WultschDepartment of Experimental and Clinical Pharmacology, Medical University of Graz, Universitätsplatz 4, A-8010 Graz, Austria.
Evelin Painsipp
Sabine Donner
Günther Sperk
Herbert Herzog
Bernhard A Peskar
Peter Holzer
Medical University of Graz · ATGarvan Institute of Medical Research · AUUniversität Innsbruck · AT

Funding

Austrian Science Fund FWF L 25
6 · The paper itself

Abstract

Neuropeptide-Y (NPY) is involved in the regulation of ingestive behaviour and energy homeostasis. Since deletion of the NPY Y2 and Y4 receptor gene increases and decreases food intake, respectively, we examined whether water intake during the light and dark phases is altered in Y2 and Y4 receptor knockout mice. The water consumption of mice staying in their home cages was measured by weighing the water bottles at the beginning and end of the light phase during 4 consecutive days. Control, Y2 and Y4 receptor knockout mice did not differ in their water intake during the light phase. However, during the dark phase Y2 and Y4 receptor knockout mice drank significantly more (46-63%, P<0.05) water than the control mice. The total daily water intake over 24 h was also enhanced. The enhanced water intake during the dark phase was not altered by the beta-adrenoceptor antagonist propranolol or the angiotensin AT1 receptor antagonist telmisartan (each injected intraperitoneally at 10 mg/kg). These data indicate that NPY acting via Y2 and Y4 receptors plays a distinctive role in the regulation of nocturnal water consumption. While beta-adrenoceptors and angiotensin AT1 receptors do not seem to be involved, water intake in Y2 and Y4 receptor knockout mice may be enhanced because presynaptic autoinhibition of NPY release and inhibition of orexin neurons in the central nervous system are prevented.

Indexed as

Adrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAnimalsBehavior, AnimalBenzimidazolesBenzoatesCircadian RhythmDrinkingMiceMice, Inbred C57BLMice, KnockoutPropranololReceptors, Neuropeptide YTelmisartanTime FactorsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsBenzimidazolesBenzoatesneuropeptide Y2 receptorneuropeptide Y4 receptorPropranololReceptors, Neuropeptide YTelmisartan

Identifiers

PMID16364461
PMCPMC4370833
OpenAlexW2030181875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.